Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878423 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT00878423 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT00878423, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.
Interventions
- DRUG AT13387
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878423
The ClinicalTrials.gov registry entry for NCT00878423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AT13387 is the first listed.
NCT00878423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878423 about?
NCT00878423 is a clinical study titled "Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors". AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effec...
What is the current status of trial NCT00878423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2008-05. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00878423?
The interventions under investigation include: AT13387 (DRUG).
Who is sponsoring clinical trial NCT00878423?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.